The investigators recorded any adverse events, calculated the albumin-creatinine ratios from urine samples at baseline and 1 year, and measured the mean arterial pressure, Dr. Jampol explained.
At 1 year, a small number of adverse events occurred (non-fatal myocardial infarctions, non-fatal strokes, and any Antiplatelet Trialists’ Collaboration event). No significant difference was seen among the 3 drugs regarding the numbers of adverse events. In addition, no relationships were seen among the VEGF levels and the mean arterial pressure.
However, an interesting finding regarding proteinuria might result in a change in some practices, Dr. Jambol pointed out.
“When we analyzed the urine samples in the study patients, we found no proteinuria in about one third of patients, microalbuminuria in about one third of patients, and very surprisingly, macroalbuminuria in about one third of patients,” Dr. Jampol said. “This suggests that we should be paying attention to the kidneys as the patients are being treated for diabetic macular edema.”
However, no difference was seen among the 3 drugs.